*001405254
*00520230401061909.0
*007cr
*007ta
*008110329s1996    no#           000 0 eng
*00901637cam a2200433 c 4500
*015  $a9613346$2nbf
*019  $bl
*020  $a8299410703$qh.
*035  $a(EXLNZ-47BIBSYS_NETWORK)999623350964702201
*035  $a(NO-LaBS)14057337(bibid)
*035  $a(NO-TrBIB)100158609
*035  $a(NO-TrBIB)962335096
*035  $a962335096-47bibsys_network
*040  $aNO-OsNB$bnob$ekatreg
*042  $anorbibl
*044  $cno
*060 4$aWJ
*060 4$aWJ 752
*080  $a616.65-007.61
*08274$a616.6$qNO-OsNB$24/nor
*1001 $aEri, Lars Magne$d1949-$0(NO-TrBIB)90946851$_243660400
*24510$aMedical treatment of benign prostatic hyperplasia (BPH) :$bclinical studies of the LHRH agonist leuprolide depot (Procren) and the nonsteroidal antiandrogen bicalutamide (Casodex)$cLars Magne Eri
*260  $aOslo$bDepartment of Surgery, Division of Urology, Ullevaal Hospital, University of Oslo$c1996
*300  $a1 b. (flere pag.)$bill.$c30 cm
*500  $aDelvis opptrykk av artikler
*502  $aAvhandling (dr. med.) - Universitetet i Oslo, 1996
*533  $aElektronisk reproduksjon$b[Norge]$cNasjonalbiblioteket Digital$d2008-07-21
*650 2$aAcademic Dissertations [PT]$_13320400
*650 2$aAndrogen Antagonists$xtherapeutic use$_69146400
*650 2$aDissertations, academic$_10492300
*650 2$aGonadorelin$xtherapeutic use$_69146500
*650 2$aProstatic Hyperplasia$xDrug therapy$_55000200
*650 2$aProstatic Hyperplasia$xtherapy$_69146600
*85641$3Fulltekst$uhttps://urn.nb.no/URN:NBN:no-nb_digibok_2008072104126$yNettbiblioteket$zDigital representasjon
*901  $a90
*913  $aNorbok$bNB
*917  $ad
*999  $aoai:nb.bibsys.no:999623350964702202$b2021-11-14T20:18:10Z$z999623350964702202
^